PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Hyaluronidase-fihj

Drugs in development · updated 30 October 2026

Hyaluronidase-fihj: clinical trials and development status

Other names and codes: Hyaluronoglucosaminidase, Hydase, Amphadase, Vitrase, Vitragan

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Hyaluronidase-fihj is in 29 active clinical trials (recruiting or ongoing, phases I–III) for 34 diseases. The most advanced phase is III.

29Active trials
IIIMost advanced phase
34Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Hyaluronidase-fihj and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 34 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Multiple myelomaIII4NCT04566328
Diffuse large B-cell lymphomaII–III2NCT04799275
Immunoglobulin Light-chain AmyloidosisIII2NCT06022939
Lymphoma, B-Cell, Marginal ZoneII–III2NCT04799275
Mantle cell lymphomaIII2NCT03267433
NeoplasmIII2NCT05256225
Burkitt lymphomaII–III1NCT07724457
Cutis laxaIII1NCT07734740
Endometrial neoplasmIII1NCT05256225
PainIII1NCT07734740
Breast neoplasmII2NCT06100874
StrokeII2NCT06718413
Abnormal reflexII1NCT03306615
Cerebral palsyII1NCT03306615
Chronic lymphocytic leukemiaII1NCT03467867
LeukemiaII1NCT03467867
Lymphoproliferative disordersII1NCT03467867
Precursor T-cell lymphoblastic leukemiaII1NCT05289687
SpasticityII1NCT03306615
Triple-negative breast neoplasmII1NCT05020860
B-cell lymphomaI1NCT04447716
Follicular lymphomaI1NCT04447716
Acute myeloid leukemiaEarly I1NCT06398457
Aplastic anemiaEarly I1NCT06398457
Autoimmune diseaseEarly I1NCT07697274
Hematologic neoplasmEarly I1NCT06398457
Hodgkin lymphomaEarly I1NCT06398457
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveEarly I1NCT06398457
LymphomaEarly I1NCT06398457
Myelodysplastic SyndromesEarly I1NCT06398457

Everything on Hyaluronidase-fihj

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch